Oruka Therapeutics SVP exercises options, sells shares
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported option exercises and share sales in Oruka Therapeutics, Inc. stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported option exercises and share sales in Oruka Therapeutics, Inc. stock. On 2026-08-13 he exercised options for 10,000 shares of common stock (8,542 at $12.50 and 1,458 at $34.39 per share) and on the same date sold 10,000 shares in multiple transactions at weighted average prices between $104.6734 and $108.4628 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($910K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Agarwal Arjun
Role
Senior Vice President, Finance
Sold
10,000 shs ($1.07M)
Approx. gross sale proceeds
$1.07M
Approx. exercise cost
$157K
Approx. pre-tax spread
$910K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F7 | 8,542 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F8 | 1,458 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,542 | $12.50 | $107K |
| Exercise | Common Stock | 1,458 | $34.39 | $50K |
| Sale | Common Stock F1, F2 | 2,100 | $104.6734 | $220K |
| Sale | Common Stock F1, F3 | 2,132 | $105.5716 | $225K |
| Sale | Common Stock F1, F4 | 1,268 | $106.6255 | $135K |
| Sale | Common Stock F1, F5 | 2,142 | $107.7138 | $231K |
| Sale | Common Stock F1, F6 | 2,358 | $108.4628 | $256K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 152,709 contracts (Direct);
Common Stock — 15,312 shares (Direct)
Footnotes (8)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.
- F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- F8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Key Figures
Options exercised: 10,000 shares
Exercise price tranche 1: $12.50 per share
Exercise price tranche 2: $34.39 per share
+5 more
8 metrics
Options exercised
10,000 shares
Total common shares underlying options exercised on 2026-08-13
Exercise price tranche 1
$12.50 per share
Exercise price for 8,542 options into common stock
Exercise price tranche 2
$34.39 per share
Exercise price for 1,458 options into common stock
Shares sold
10,000 shares
Total common shares sold in multiple transactions on 2026-08-13
Lowest reported sale price
$104.6734 per share
Weighted average price for one sale tranche of 2,100 shares
Highest reported sale price
$108.4628 per share
Weighted average price for one sale tranche of 2,358 shares
Rule 10b5-1 plan date
February 11, 2026
Date the trading plan governing these sales was entered into
Option expiration dates
2035-01-21 and 2036-01-22
Expiration dates for the two employee stock option grants
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average price, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
non-derivative financial
"transaction_type: non-derivative for Common Stock sale entries"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Oruka Therapeutics (ORKA) executive Arjun Agarwal report in this Form 4?
Arjun Agarwal reported exercising options for 10,000 shares of Oruka Therapeutics, Inc. common stock and Selling 10,000 shares in multiple transactions on 2026-08-13, according to the Form 4 filing.
How many Oruka Therapeutics (ORKA) options did Agarwal exercise and at what prices?
Agarwal exercised options covering 10,000 shares, consisting of 8,542 shares at an exercise price of $12.50 per share and 1,458 shares at an exercise price of $34.39 per share.
What vesting terms applied to the Oruka Therapeutics (ORKA) options exercised by Agarwal?
One option covering 8,542 shares vests as to 1/48 of the underlying shares monthly from January 1, 2025, and another for 1,458 shares vests monthly from January 1, 2026, as disclosed in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates